Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
Public ClinicalTrials.gov record NCT01147809. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.
Study identification
- NCT ID
- NCT01147809
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 130 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2010 (Type not available)
- Primary completion
- Jan 2015 (Actual)
- Completion
- Mar 2015 (Actual)
- Last update posted
- Apr 18, 2016
2010 – 2015
United States locations
- U.S. sites
- 33
- U.S. states
- 20
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Sedona | Arizona | 86336 | — |
| GSK Investigational Site | Hot Springs | Arkansas | 71913 | — |
| GSK Investigational Site | Rancho Cucamonga | California | 91730 | — |
| GSK Investigational Site | Norwich | Connecticut | 06360 | — |
| GSK Investigational Site | Jacksonville | Florida | 32256 | — |
| GSK Investigational Site | New Port Richey | Florida | 34655 | — |
| GSK Investigational Site | Rome | Georgia | 30165 | — |
| GSK Investigational Site | Savannah | Georgia | 31405 | — |
| GSK Investigational Site | Wichita | Kansas | 67214 | — |
| GSK Investigational Site | Bethesda | Maryland | 20817 | — |
| GSK Investigational Site | Rockville | Maryland | 20850 | — |
| GSK Investigational Site | Columbia | Missouri | 65201 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89169 | — |
| GSK Investigational Site | Cherry Hill | New Jersey | 08003 | — |
| GSK Investigational Site | Albany | New York | 12206 | — |
| GSK Investigational Site | Greensboro | North Carolina | 27403 | — |
| GSK Investigational Site | Bend | Oregon | 97701 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19106 | — |
| GSK Investigational Site | Wynnewood | Pennsylvania | 19096 | — |
| GSK Investigational Site | Providence | Rhode Island | 02903 | — |
| GSK Investigational Site | Providence | Rhode Island | 02906 | — |
| GSK Investigational Site | Greenville | South Carolina | 29605 | — |
| GSK Investigational Site | Arlington | Texas | 76014 | — |
| GSK Investigational Site | Austin | Texas | 78731 | — |
| GSK Investigational Site | Bedford | Texas | 76022 | — |
| GSK Investigational Site | Dallas | Texas | 75246 | — |
| GSK Investigational Site | San Antonio | Texas | 78217 | — |
| GSK Investigational Site | Tyler | Texas | 75702 | — |
| GSK Investigational Site | Norfolk | Virginia | 23502 | — |
| GSK Investigational Site | Edmonds | Washington | 98026 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
| GSK Investigational Site | Vancouver | Washington | 98684 | — |
| GSK Investigational Site | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01147809, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 18, 2016 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01147809 live on ClinicalTrials.gov.